PST
DEAD

Serial Number

97705184

Owner

Adaptive Phage Therapeutics, Inc.

Attorney

Leesa N. Weiss

Filing Date

Dec 6, 2022

Add to watchlist:

No watchlists yet
View on USPTO

PST Trademark

Serial Number: 97705184

PST is a trademark filed by Adaptive Phage Therapeutics, Inc. on December 6, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Adaptive Phage Therapeutics, Inc. (25 trademarks)

Gaithersburg, MD 20878

Entity Type: 03

Trademark Details

Filing Date

December 6, 2022

Registration Date

Not Registered

Published for Opposition

April 18, 2023

Goods & Services

new product research and development in the fields of personalized medicine and diagnostics; data mining of healthcare and genetic information in the field of precision medicine and personalized medicine; scientific study and research in the fields of biochemistry, disease, personalized medicine, personalized therapeutics, and pharmaceuticals; medical laboratory services and scientific laboratory services in the nature of clinical and medical laboratory services for medical research purposes in the fields of disease diagnostics and personalized medicine; pharmaceutical drug research and development; custom biochemical assay development; pharmaceutical drug discovery and development services; providing laboratory research services in the field of medical diagnostics and personalized medicine; medical research services; biotechnology research; providing medical and scientific research information in the field of clinical trials; new product research and development of vaccines and therapeutics; providing temporary use of online non-downloadable computer software application in the field of personalized medicine to provide medical and diagnostic services involving bacterial infections; medical research, namely, providing medical diagnostic assays and diagnostic and prognostic testing for medical research purposes of bacterial infections and the analysis, evaluation and reporting of those test results to help healthcare professionals for research purposes; development of new technology for others in the field of biotechnology; laboratory research in the field of genomic sequencing; research and development in the pharmaceutical and biotechnology fields; research development, engineering and testing services in the fields of bacteria and viruses; laboratory research in the field of infectious diseases; medical and scientific research in the field of immunotherapy; medical laboratory services; laboratory research services in the field of microbiological laboratory testing of bacteria for research purposes and technical consultation relating thereto; scientific and medical research, in particular, design and development of diagnostic assays; medical laboratory services in the nature of testing services for diagnostic purposes in the fields of disease diagnostics and personalized medicine; medical laboratory services in the nature of microbiological laboratory testing of bacteria for diagnostic and medical purposes, and technical consultation thereto

medical testing for diagnostic or treatment purposes in the field of personalized medicine; health care services, namely, providing a database in the field of personalized medicine and featuring inputting and collection of data and information all for treatment and diagnostic purposes; medical testing for diagnostic or treatment purposes, namely, providing medical diagnostic assays and diagnostic and prognostic testing for treatment purposes of bacteria infections and the analysis, evaluation, and reporting of those test results to help healthcare professionals determine a patient's clinical diagnosis, the effectiveness of patient treatments, and to revise future treatments accordingly; medical services; medical consulting services in the field of medical diagnostic and prognostic testing; medical services in the nature of medical analysis services for diagnostic and prognostic testing and treatment purposes; medical analysis services relating to the diagnosis and treatment of a person; medical testing and medical diagnostic services for diagnostic or treatment purposes, in particular performing tests using diagnostic assays

human, animal, plant and microorganism biological preparations for disease modeling and personalized medicine to prevent or treat bacterial infectious diseases; bactericides, namely, biological preparations to treat bacterial infections and bacterial contamination in the field of medicine; diagnostic kits comprising medical diagnostic reagents for testing bacteria sensitivity

diagnostic reagents for clinical and medical laboratory use; diagnostic kits comprising diagnostic reagents for testing bacteria sensitivity, except for medical or veterinary use; human, animal, plant and microorganism biological preparations for use in industry and science, namely, for use in drug development; Biological preparations for use in industry and science, namely, for treating bacterial contamination in the fields of farming and food preparation; Biological preparations for use in industry and science, namely, for treating bacterial contamination in the industrial and food preparation fields

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jan 19, 2026 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jan 19, 2026 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 6, 2025 EXRA
SOU EXTENSION 4 GRANTED
May 5, 2025 EX4G
SOU EXTENSION 4 FILED
May 5, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
May 5, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 3, 2025 EXRA
SOU EXTENSION 3 GRANTED
May 2, 2025 EX3G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Mar 25, 2025 AITU
SOU EXTENSION 3 FILED
Dec 3, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Dec 3, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 16, 2024 EXRA
SOU EXTENSION 2 GRANTED
May 15, 2024 EX2G
SOU EXTENSION 2 FILED
May 15, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
May 15, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 8, 2023 EXRA
SOU EXTENSION 1 GRANTED
Dec 6, 2023 EX1G
SOU EXTENSION 1 FILED
Dec 6, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 6, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 13, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 18, 2023 NPUB
PUBLISHED FOR OPPOSITION
Apr 18, 2023 PUBO
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 4, 2023 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 4, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 4, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 4, 2023 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Apr 4, 2023 COAR
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 29, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 14, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 14, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 14, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 14, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 14, 2023 CNEA
ASSIGNED TO EXAMINER
Mar 6, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 9, 2022 NWOS
NEW APPLICATION ENTERED
Dec 9, 2022 NWAP